2021
DOI: 10.3390/microorganisms9040880
|View full text |Cite
|
Sign up to set email alerts
|

Ambroxol Treatment Suppresses the Proliferation of Chlamydia pneumoniae in Murine Lungs

Abstract: Ambroxol (Ax) is used as a mucolytics in the treatment of respiratory tract infections. Ax, at a general dose for humans, does not alter Chlamydia pneumoniae growth in mice. Therefore, we aimed to investigate the potential anti-chlamydial effect of Ax at a concentration four timed higher than that used in human medicine. Mice were infected with C. pneumoniae and 5-mg/kg Ax was administered orally. The number of recoverable C. pneumoniae inclusion-forming units (IFUs) in Ax-treated mice was significantly lower … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 51 publications
(72 reference statements)
0
1
0
Order By: Relevance
“…While NAC increased CP infection, ambroxol did not impact CP growth in mice at clinically relevant concentrations [27]. The 4-fold increased ambroxol concentration (still tolerable in vivo ), however, suppressed CP proliferation in murine lungs, leading the authors to conclude that ambroxol could be used as a supportive drug to treat chlamydial respiratory infections [28]. Whether these pharmaceutical interactions with chlamydial development will ultimately be applied in the clinical setting remains to be seen.…”
Section: Introductionmentioning
confidence: 99%
“…While NAC increased CP infection, ambroxol did not impact CP growth in mice at clinically relevant concentrations [27]. The 4-fold increased ambroxol concentration (still tolerable in vivo ), however, suppressed CP proliferation in murine lungs, leading the authors to conclude that ambroxol could be used as a supportive drug to treat chlamydial respiratory infections [28]. Whether these pharmaceutical interactions with chlamydial development will ultimately be applied in the clinical setting remains to be seen.…”
Section: Introductionmentioning
confidence: 99%